<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0000855'>Insulin resistance</z:hpo> underlies the pathogenesis of <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and <z:e sem="disease" ids="C0007222" disease_type="Disease or Syndrome" abbrv="CVD">cardiovascular disease</z:e> in most people with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> and <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> (<z:chebi fb="0" ids="8228">pioglitazone</z:chebi> and <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>) counter <z:hpo ids='HP_0000855'>insulin resistance</z:hpo> by different cellular mechanisms and with complementary effects, making them suited for use in combination </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> exerts a stronger suppression of hepatic <z:chebi fb="105" ids="17234">glucose</z:chebi> output, while <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> produce a greater increase in peripheral <z:chebi fb="105" ids="17234">glucose</z:chebi> uptake, enabling <z:chebi fb="0" ids="6801">metformin</z:chebi>-thiazolidinedione combinations to improve glycaemic control in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> with additive efficacy </plain></SENT>
<SENT sid="3" pm="."><plain>Basal insulin concentrations are not raised by <z:chebi fb="0" ids="6801">metformin</z:chebi> or <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi>, so there is minimal risk of <z:e sem="disease" ids="C0020615" disease_type="Disease or Syndrome" abbrv="">hypoglycaemia</z:e>, and <z:chebi fb="0" ids="6801">metformin</z:chebi> can reduce the <z:mp ids='MP_0005456'>weight gain</z:mp> associated with <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain>There are overlapping effects of <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> against a range of athero-thrombotic factors and markers </plain></SENT>
<SENT sid="5" pm="."><plain>These include decreased plasminogen activator inhibitor-1, <z:mp ids='MP_0009549'>reduced platelet aggregation</z:mp>, reductions of several vascular <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecules, and reduced markers of low-grade <z:mp ids='MP_0001845'>inflammation</z:mp> such as C-reactive protein </plain></SENT>
<SENT sid="6" pm="."><plain>Additionally, <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> increase adiponectin and slightly reduce blood pressure </plain></SENT>
<SENT sid="7" pm="."><plain>Both <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> can improve components of the <z:chebi fb="23" ids="18059">lipid</z:chebi> profile: <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> consistently reduce free fatty acid concentrations and decrease the proportion of small dense <z:chebi fb="2" ids="39026">low-density-lipoprotein</z:chebi>, and <z:chebi fb="0" ids="8228">pioglitazone</z:chebi> also decreases <z:chebi fb="4" ids="17855">triglycerides</z:chebi> </plain></SENT>
<SENT sid="8" pm="."><plain>During co-administration, <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> do not interfere with each other's pharmacokinetics, and lower doses of the two agents together can achieve efficacy with fewer side effects </plain></SENT>
<SENT sid="9" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi>-thiazolidinedione combinations require attention to the precautions for both agents, especially renal, cardiac and hepatic status </plain></SENT>
<SENT sid="10" pm="."><plain>Thus, <z:chebi fb="0" ids="6801">metformin</z:chebi> and <z:chebi fb="0" ids="50864">thiazolidinediones</z:chebi> can be used in combination to address the <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e> and vascular risk in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
</text></document>